Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer.

MLA

Michio Noda, et al. “Comparison of Oncological Outcomes of Upfront Androgen Receptor Signaling Inhibitors and Combined Androgen Blockade in Japanese Patients with Metastatic Castration-Sensitive Prostate Cancer.” Global Health & Medicine, vol. 6, no. 3, June 2024, pp. 199–203. EBSCOhost, https://doi.org/10.35772/ghm.2024.01019.

APA

Michio Noda, Taketo Kawai, Kanade Hagiwara, Takahiro Yoshida, Kazuki Yanagida, Yuumi Tokura, Itsuki Yoshimura, Tomoyuki Kaneko, & Tohru Nakagawa. (2024). Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer. Global Health & Medicine, 6(3), 199–203. https://doi.org/10.35772/ghm.2024.01019

Chicago

Michio Noda, Taketo Kawai, Kanade Hagiwara, Takahiro Yoshida, Kazuki Yanagida, Yuumi Tokura, Itsuki Yoshimura, Tomoyuki Kaneko, and Tohru Nakagawa. 2024. “Comparison of Oncological Outcomes of Upfront Androgen Receptor Signaling Inhibitors and Combined Androgen Blockade in Japanese Patients with Metastatic Castration-Sensitive Prostate Cancer.” Global Health & Medicine 6 (3): 199–203. doi:10.35772/ghm.2024.01019.